Search research articles
Contact Us
Filters
Showing results (301-310 of 357) with videos related to
Page
of 36
Sort By:
Die Pharmazie
|
October 20, 2007
Targeted intracellular delivery of therapeutics: an overview
A Rawat, B Vaidya, K Khatri, et al.
JCI Insight
|
January 23, 2026
The RNA binding protein Arid5a is an activator of TNF signaling in rheumatoid arthritis
Yang Li, Ipsita Dey, Shachi P Vyas, et al.
Cancer Research
|
August 1, 1982
Mutagenicity of the optical isomers of the diastereomeric bay-region chrysene 1,3-diol-3,4-epoxides in bacterial and mammalian cells
A W Wood, R L Chang, W Levin, et al.
Vaccine
|
May 18, 2011
Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally
Sharad Mangal, Dilip Pawar, Neeraj K Garg, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 1, 1993
Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human
R A Halpin, E H Ulm, A E Till, et al.
Journal of Biomedical Nanotechnology
|
January 9, 2010
Efficient tumor targeting by polysaccharide decked polyethylenimine based nanocomposites
Atul Pathak, Archana Swami, Soma Patnaik, et al.
Cancer Research
|
January 1, 1983
Tumorigenicity of enantiomers of chrysene 1,2-dihydrodiol and of the diastereomeric bay-region chrysene 1,2-diol-3,4-epoxides on mouse skin and in newborn mice
R L Chang, W Levin, A W Wood, et al.
Current Medicinal Chemistry
|
August 19, 2007
Estrogen(s) and analogs as a non-immunogenic endogenous ligand in targeted drug/DNA delivery
Shivani Rai, Rishi Paliwal, Bhuvaneshwar Vaidya, et al.
Oncogene
|
May 13, 1999
Mrvi1, a common MRV integration site in BXH2 myeloid leukemias, encodes a protein with homology to a lymphoid-restricted membrane protein Jaw1
J D Shaughnessy, D A Largaespada, E Tian, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
May 1, 1993
In vivo and in vitro metabolism studies on a class III antiarrhythmic agent
S Vickers, C A Duncan, P H Kari, et al.
Page
of 36
Search research articles
Search
Showing results (301-310 of 357) with videos related to
Sort By:
Page
of 36
Die Pharmazie
|
October 20, 2007
Targeted intracellular delivery of therapeutics: an overview
A Rawat, B Vaidya, K Khatri, et al.
JCI Insight
|
January 23, 2026
The RNA binding protein Arid5a is an activator of TNF signaling in rheumatoid arthritis
Yang Li, Ipsita Dey, Shachi P Vyas, et al.
Cancer Research
|
August 1, 1982
Mutagenicity of the optical isomers of the diastereomeric bay-region chrysene 1,3-diol-3,4-epoxides in bacterial and mammalian cells
A W Wood, R L Chang, W Levin, et al.
Vaccine
|
May 18, 2011
Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally
Sharad Mangal, Dilip Pawar, Neeraj K Garg, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 1, 1993
Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human
R A Halpin, E H Ulm, A E Till, et al.
Journal of Biomedical Nanotechnology
|
January 9, 2010
Efficient tumor targeting by polysaccharide decked polyethylenimine based nanocomposites
Atul Pathak, Archana Swami, Soma Patnaik, et al.
Cancer Research
|
January 1, 1983
Tumorigenicity of enantiomers of chrysene 1,2-dihydrodiol and of the diastereomeric bay-region chrysene 1,2-diol-3,4-epoxides on mouse skin and in newborn mice
R L Chang, W Levin, A W Wood, et al.
Current Medicinal Chemistry
|
August 19, 2007
Estrogen(s) and analogs as a non-immunogenic endogenous ligand in targeted drug/DNA delivery
Shivani Rai, Rishi Paliwal, Bhuvaneshwar Vaidya, et al.
Oncogene
|
May 13, 1999
Mrvi1, a common MRV integration site in BXH2 myeloid leukemias, encodes a protein with homology to a lymphoid-restricted membrane protein Jaw1
J D Shaughnessy, D A Largaespada, E Tian, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
May 1, 1993
In vivo and in vitro metabolism studies on a class III antiarrhythmic agent
S Vickers, C A Duncan, P H Kari, et al.
Page
of 36